PURPOSE: Alzheimer's disease (AD) may disturb functions of the blood-brain barrier and change the disposition of drugs to the brain. This study assessed the disease-induced changes in drug transporters in the brain capillaries of transgenic AD mice. METHODS: Eighteen drug transporters and four tight junction-associated proteins were analyzed by RT-qPCR in cortex, hippocampus and cerebellum tissue samples of 12-16-month-old APdE9, Tg2576 and APP/PS1 transgenic mice and their healthy age-matched controls. In addition, microvessel fractions enriched from 1-3-month-old APdE9 mice were analyzed using RT-qPCR and Western blotting. Brain transport of methotrexate in APdE9 mice was assessed by in vivo microdialysis. RESULTS: The expression profiles of studied genes were similar in brain tissues of AD and control mice. Instead, in the microvessel fraction in APdE9 mice, >2-fold alterations were detected in the expressions of 11 genes but none at the protein level. In control mice strains, >5-fold changes between different brain regions were identified for Slc15a2, Slc22a3 and occludin. Methotrexate distribution into hippocampus of APdE9 mice was faster than in controls. CONCLUSIONS: The expression profile of mice carrying presenilin and amyloid precursor protein mutations is comparable to controls, but clear regional differences exist in the expression of drug transporters in brain.
PURPOSE:Alzheimer's disease (AD) may disturb functions of the blood-brain barrier and change the disposition of drugs to the brain. This study assessed the disease-induced changes in drug transporters in the brain capillaries of transgenic ADmice. METHODS: Eighteen drug transporters and four tight junction-associated proteins were analyzed by RT-qPCR in cortex, hippocampus and cerebellum tissue samples of 12-16-month-old APdE9, Tg2576 and APP/PS1transgenic mice and their healthy age-matched controls. In addition, microvessel fractions enriched from 1-3-month-old APdE9 mice were analyzed using RT-qPCR and Western blotting. Brain transport of methotrexate in APdE9 mice was assessed by in vivo microdialysis. RESULTS: The expression profiles of studied genes were similar in brain tissues of AD and control mice. Instead, in the microvessel fraction in APdE9 mice, >2-fold alterations were detected in the expressions of 11 genes but none at the protein level. In control mice strains, >5-fold changes between different brain regions were identified for Slc15a2, Slc22a3 and occludin. Methotrexate distribution into hippocampus of APdE9 mice was faster than in controls. CONCLUSIONS: The expression profile of mice carrying presenilin and amyloid precursor protein mutations is comparable to controls, but clear regional differences exist in the expression of drug transporters in brain.
Authors: Anika M S Hartz; Björn Bauer; Emma L B Soldner; Andrea Wolf; Sandra Boy; Roland Backhaus; Ivan Mihaljevic; Ulrich Bogdahn; Hans H Klünemann; Gerhard Schuierer; Felix Schlachetzki Journal: Stroke Date: 2011-11-23 Impact factor: 7.914
Authors: Ilaria Badagnani; Richard A Castro; Travis R Taylor; Claire M Brett; Conrad C Huang; Douglas Stryke; Michiko Kawamoto; Susan J Johns; Thomas E Ferrin; Elaine J Carlson; Esteban G Burchard; Kathleen M Giacomini Journal: J Pharmacol Exp Ther Date: 2006-05-15 Impact factor: 4.030
Authors: Anna Carrano; Hripsime Snkhchyan; Gijs Kooij; Susanne van der Pol; Jack van Horssen; Robert Veerhuis; Jeroen Hoozemans; Annemieke Rozemuller; Helga E de Vries Journal: Neurobiol Aging Date: 2013-10-15 Impact factor: 4.673
Authors: Ahmed Montaser; Johanna Huttunen; Sherihan Abdelhamid Ibrahim; Kristiina M Huttunen Journal: Oxid Med Cell Longev Date: 2019-11-13 Impact factor: 6.543
Authors: Mikko Gynther; Elena Puris; Soile Peltokangas; Seppo Auriola; Katja M Kanninen; Jari Koistinaho; Kristiina M Huttunen; Marika Ruponen; Kati-Sisko Vellonen Journal: Pharm Res Date: 2018-11-28 Impact factor: 4.200